Group Beliefs Regarding Suffering: The Case of Expert Choice of Melanoma Drug

Authors

  • Sergey Y. Shevchenko Институт философии РАН , Institute of Philosophy Автор

DOI:

https://doi.org/10.22394/2074-0492-2017-3-144-162

Keywords:

evidence, group beliefs, body, operationalism, knowledge and belief, MEDICAL statistics, regulation in medicine

Abstract

This article deals with pragmatic coexistence of several competing ontologies of the body and possibility of their reconstruction through epistemic phenomena, including group beliefs. In this regard, the research problem is the possibility of supplementing pragmatic consideration of forms of ontological coordination by the epistemological account of group reasoning in biomedicine. Decision making in the field ontological politics is considered to correspond to stabilizing the scientific fact in the epistemic field. Methods of social epistemology are used for reconstructing of this process. Forms of ontological coordination in this context does not appear as communication between different practices and points of view, but as a result of simultaneous coexistence of plural ontologies in the process of justifying a collective decision. Preparation of the guideline by the expert group of the British health regulator NICE is taken as case of such coexistence. NICE guideline contains recommendations for the administration of the drug ipilimumab to patients with metastatic melanoma for "default" use. These recommendations seem to go beyond the methodology of evidence-based medicine, based on its own ontology of bodily suffering. The search for other grounds for expert choice indicates two types of collective epistemic phenomena: group beliefs and group acceptances. Group beliefs have an epistemic basis and can be examined in the field of social epistemology. Group acceptances seem to be opaque for epistemology, and can be analyzed only through the social conditions of their formation. Thus, several dimensions of the epistemic reasoning of group decision are highlighted: 1) explicit knowledge, 2) group beliefs and 3) group acceptances.

Downloads

Download data is not yet available.

References

Агацци Э. (2015) Научная объективность и ее контексты, М.: Три квадрата.

Борисов Н. (2014) FAQ: Таргетные препараты в онкологии. Постанаука (https:// postnauka.ru/faq/27800)

Невинная И. (2016) Приговор отменяется: уникальный препарат от рака кожи получил первый пациент. Российская газета. Федеральный выпуск. 7164 (296) (https:// rg.ru/2016/12/28/skvorcova-rasskazala-ob-uspehah-v-razrabotke-preparata-ot-raka-kozhi.html)

Armstrong D. (1962) Bodily sensations, London: Routledge and Paul.

Bloor D. (1991) Knowledge and Social Imagery. 2 ed., Chicago; London: The University of Chicago Press.

Burstrom С., Johannesson M., Diderichsen F. et al. (2006) A comparison of individual and social time-trade-off values for health states in the general population. Health Policy, 76 (3): 359-370.

Casey Quinn, Qiufei Ma, Amber Kudlac et al. (2016) Indirect Treatment Comparison of Talimogene Laherparepvec Compared with Ipilimumab and Vemurafenib for the Treatment of Patients with Metastatic Melanoma. Advances in Therapy, 33: 643-657.

Chignell A. (2017) The Ethics of Belief. The Stanford Encyclopedia of Philosophy. E.N.Zalta (ed.) (https://plato.stanford.edu/archives/spr2017/entries/ethics-belief/)

Dzienis M.R., Atkinson V.G. (2014) Response rate to vemurafenib in patients with B-RAF-positive melanoma brain metastases: a retrospective review. Melanoma Res., 24 (4): 349-353.

Hakli R. (2006) Group beliefs and the distinction between belief and acceptance. Cognitive Systems Research, 7 (2-3): 286-297

Hatzivassiliou G., Song K., Yen I., Brandhuber B.J., Anderson D.J. et al. (2010) RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth. Nature, 464 (7287): 431-435.

Hintikka J. (1962) Knowledge and Belief-An Introduction to the Logic of the Two Notions, Ithaca; N.Y.: Cornell University Press.

Ipilimumab for previously treated advanced (unresectable or metastatic) melanoma (2012) NICE (https://www.nice.org.uk/guidance/ta268)

Lackey J. (2013) Group Belief: Lessons from Lies and Bullshit: доклад на 100-м заседании семинара «Проблемы рациональной философии". Институт философии РАН (http://iphras.ru/uplfile/soce)

Measuring effectiveness and cost effectiveness: the QALY (2010; Retrieved 15 Jun 2015). NICE (https://www.nice.org.uk/process/pmg9/chapter/1-foreword)

Mol A. (1999) Ontological politics. A word and some questions. The Sociological Review, (47): 74-89.

Mol A. (2002) The Body Multiple: ontology in medical practice, Durham; NC: Duke University Press.

NICE proposes ipilimumab as a first treatment for advanced skin cancer (s.d.). NICE (https://www.nice.org.uk/news/press-and-media/nice-proposes-ipilimumab-as-a-first-treatment-for-advanced-skin-cancer)

NICE recommends vemurafenib as a possible treatment for unresectable or metastatic melanoma with the BRAF V600 mutation. (s.d.). NICE. (https://www.nice.org. uk/guidance/ta269?unlid)

Ribas A. (2012) Tumor immunotherapy directed at PD-1. New England Journal of Medicine, 366 (26): 2517-2519.

Schadendorf D., Hodi F., Stephen R., Weber J.S. et al. (2015) Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma JCO: 1889-1894.

Schmitt F.F. (2014) Group Belief and Acceptance. From Individual to Collective Intention-ality: New Essays, Oxford University Press.

Whitehead S.J., Ali S. (2010) Health outcomes in economic evaluation: the QALY and utilities. Br. Med. Bull., 96 (1): 5-21

Downloads

Published

2017-05-15

Issue

Section

Articles

How to Cite

Shevchenko S.Y. Group Beliefs Regarding Suffering: The Case of Expert Choice of Melanoma Drug // Sociology of Power. 2017. Vol. 29, no. 3. P. 144–162. https://doi.org/10.22394/2074-0492-2017-3-144-162

Коды статьи

  • EDN YTPUKA
  • Тип статьи (РИНЦ) Научная статья (Научная статья)